Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod in Advanced NSCLC and SCLC
NCT06424067Phase 2
Key facts
- Status
- Recruiting
- Start
- May 2025
- Primary completion
- May 2027
- Countries
- 1
- Sponsor
- Medical University of South Carolina
- Modality
- Small Molecules
- Drugs
- fingolimod
- Conditions
- non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label trial of fingolimod in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (2 arms), sponsored by Medical University of South Carolina. Primary endpoints: Safety of Fingolimod at 6 months and Response Rate at 6 months. Started May 2025; status: recruiting.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Efficacy in NSCLC
Fingolimod 0.5 mg once daily in NSCLC patients
Efficacy in SCLC
Fingolimod 0.5 mg once daily in SCLC patients
03
Who it enrols
Adult patients with advanced/metastatic NSCLC or extensive stage SCLC who have progressed on at least 2 prior lines of systemic therapy, with ECOG 0-2, adequate lymphocyte counts, and no recent cardiac events or concurrent use of interacting/QT-prolonging medications.
04
Endpoints
Primary
Safety of Fingolimod
Response Rate
Secondary
Progression-free Survival
Overall Survival
Beyond the preview
Go deeper on NCT06424067.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424067.